about
Prediction of early breast cancer metastasis from DNA microarray data using high-dimensional cox regression modelsTwo-stage design of clinical trials involving recurrent events.An R function to non-parametric and piecewise analysis of competing risks survival data.Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma: A retrospective analysis by the Association Française de Chirurgie.Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal CancerImmunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.A multicentre randomised controlled trial to evaluate the efficacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and design.Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factorsLow non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial.Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study.Friday, February 21, 2014, 5:00pm–6:30pm Oral Poster I (Liver I, II; Pancreas I, II; Biliary I; Transplant I; Other)UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.Optimal scheduling of post-therapeutic follow-up of patients treated for cancer for early detection of relapses.Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.Goodness-of-fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals.How to report toxicity associated with targeted therapies?Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.Survival after breast cancer local recurrence according to therapeutic strategies.[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.Severe Jaundice Increases Early Severe Morbidity and Decreases Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma.Assessment of health status over time by Prevalence and Weighted Prevalence functions: Interface in R.Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers.[Neuron-specific enolase (NSE) in the surveillance of small cell cancers. An evaluation of the prognostic information using Markov's model]Solid pancreatic tumors in patients younger than 40 years old--experience of a French comprehensive cancer center.Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment.Enhanced recovery after surgery program in Gynaecologic Oncological surgery in a minimally invasive techniques expert center.Early prognostic factors in septic shock cancer patients: a prospective study with a proteomic approach.Comparison of variable selection methods for high-dimensional survival data with competing events.JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia.Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study.Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts.How to Reliably Assess Nodal Status in Distal Pancreatectomy for Adenocarcinoma.Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT.Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
P50
Q30953190-09F691B3-3DD9-42C0-9075-45D21E0A4319Q33385266-5FA71A4B-0A53-4830-BF17-02A2C7E11DC8Q33546245-73710EEA-2CD4-4510-B1F4-13747B856355Q33818221-0E6E75D8-42F5-4559-B52F-7C112BA98AE8Q35593473-15B7CB9B-83C7-4842-971C-FD486C90A023Q35807180-45138B18-89F5-4B33-B5B3-8C7AAB50167BQ36343813-469ACA12-4B3E-45E6-9A55-D3C3514A89D0Q36618994-761F11DE-17B5-4FB0-B826-C39967C1C2C7Q36622856-6D40D25C-FB5C-4D42-AE6F-6C2002389D25Q36715911-49DE1C57-ED15-47D7-95C6-EC78BD8BB07DQ37427956-274650D2-104B-4BF5-A748-694E04C7159EQ37480826-5A8A9051-4460-437A-8213-A5CA350617EAQ38412031-E37971A8-B219-4741-8017-51DF1409613CQ38422132-3BC55F2D-4933-4BE7-B4A4-29CB0331E6D8Q38638751-60E087A8-7FC7-4BFE-B53F-488FF3011E3AQ38794973-198C63A5-F518-48D6-BB67-0C1835D9AC1BQ39240242-611FB98B-9527-49A8-A201-9359FAE9E891Q39741239-E911EC34-DFF8-46C0-A61E-89C46F2643DAQ39966200-D44FFD9E-94AB-458E-A85F-81B9B8750162Q40188982-29447B03-5579-4F76-929A-018413600314Q40329399-DC90A303-D7B5-45C0-BCC6-8386E1973106Q40576820-FF9CB360-B53E-424A-9F74-06D1BF6EDFFAQ40701248-B93923AA-A1A0-40B4-83A1-0970F3AF2FF4Q41524548-B4EDB1C8-5B1B-48A1-B761-E7CEEF184CA0Q42371602-04B518A6-F103-4F91-9640-FC834B0B1418Q43800142-121B6B4C-EC3E-4694-92B6-6A859CEB942AQ44732890-4D96187C-B5EA-4CC3-97EC-B5AC97CAB33FQ44743232-CF4B62D9-D8CC-4D25-B213-E443CDCF31FCQ47121810-85FCDD2A-AA46-4B95-B92E-76307F671DE5Q47218273-1D1A931F-5268-43DC-88F3-55A8AE2DC14BQ47702148-66D26F2C-1825-487E-925E-93DD1BEC114BQ47709793-AA9F63E3-1B15-4E83-9A2A-66A64BF337D5Q47711226-5FAC3D2B-6448-49A1-9F20-BA3E65D12562Q47741271-D2E074FB-6F9C-4FAB-8AE4-FE4E2D072BF6Q47912744-4DE9A77F-99A2-400A-8EB8-35E904CBB18AQ48281067-2FBBB5E1-5A0F-4AF7-B0CB-A9FD4A40983DQ49547506-302459EF-0172-4B31-8BC7-083486A25652Q49920144-D8F76A73-03E7-42F1-AC9F-0C8E1EEA515FQ50147866-D864620C-0676-4BE6-AED6-699F1F65B0C9Q50510009-13771BE2-25CC-4796-BC12-A5F874A7F65D
P50
description
researcher ORCID ID = 0000-0002-5395-839X
@en
name
Jean-Marie Boher
@ast
Jean-Marie Boher
@en
Jean-Marie Boher
@es
Jean-Marie Boher
@nl
type
label
Jean-Marie Boher
@ast
Jean-Marie Boher
@en
Jean-Marie Boher
@es
Jean-Marie Boher
@nl
prefLabel
Jean-Marie Boher
@ast
Jean-Marie Boher
@en
Jean-Marie Boher
@es
Jean-Marie Boher
@nl
P31
P496
0000-0002-5395-839X